Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
LUNG
STRONG SELLPulmonx Corporation · Healthcare · United States · $53M · Avg Vol: $564K/d
COMPANY DESCRIPTION
Pulmonx Corporation is a commercial-stage medical device company specializing in minimally invasive treatments for severe emphysema, a form of COPD. The company's flagship Zephyr Endobronchial Valve is a clinically proven, FDA-approved solution designed to improve lung function and quality of life without major surgery. Pulmonx holds a dominant market position in interventional pulmonology, supported by robust clinical evidence, global regulatory approvals, and established reimbursement pathways.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 53.7M | 68.7M | 83.8M | 90.5M | 19.0% | 88.5M | 90.8M | 98.1M | 4.1% |
| EPS | -1.59 | -1.60 | -1.44 | -1.33 | — | -1.26 | -1.14 | -1.04 | — |
| Shares | 37.6M | 38.5M | 39.8M | 41.7M | +11.0% | 42.2M | — | — | — |
| Debt | 24.4M | 41.4M | 56.5M | 56.4M | 32.2% | 56.3M | — | — | — |
| Equity | 154.0M | 118.3M | 85.8M | 54.1M | -29.4% | — | — | — | — |
| Op CF | -45.1M | -37.6M | -31.5M | -32.4M | — | -29.3M | — | — | — |
| Inv CF | -4.2M | -2.0M | 17.5M | 30.5M | — | — | — | — | — |
| Fin CF | 2.4M | 21.4M | 1.4M | 0.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LUNG are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LUNG | Pulmonx Corporation(you) | $53M | 18 | STRONG SELL |
| ARAY | Accuray Incorporated | $53M | 18 | STRONG SELL |
| MDAI | Spectral AI, Inc. | $52M | 16 | STRONG SELL |
| ECOR | electroCore, Inc. | $51M | 22 | SELL |
| COCH | Envoy Medical, Inc. | $51M | 14 | STRONG SELL |
| ELUT | Elutia Inc. | $51M | 25 | SELL |
| OM | Outset Medical, Inc. | $75M | 16 | STRONG SELL |
| LNSR | LENSAR, Inc. | $69M | 11 | STRONG SELL |
| HYPR | Hyperfine, Inc. | $95M | 13 | STRONG SELL |
| AVH.AX | AVITA Medical, Inc. | $115M | 20 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%